03.20.25 -- Are We Witnessing A New "Age Of The CDMO"?

A cost-effective approach with a comprehensive AAV analytical package holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.

Uncover why leveraging strong scientific expertise and comprehensive testing techniques will be vital in expediting development and upholding the integrity of these life-saving treatments.

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

Learn about the development and effective scale-up of a robust process for manufacturing adenovirus vectors and the obstacles that were encountered and successfully overcome.

As rare disease research continues to evolve, particularly with breakthroughs in precision medicine, the partnership between patient communities and biotech companies has never been more important.

This study compares two important mRNA capping technologies by evaluating the mRNA integrity, percent Cap1 content, dsRNA content, in vivo expression, and innate immune activation in mice.

Every choice is critical in AAV vector production. Experts share how to make the right choices, from the process and cell line, to off-the-shelf plasmids and qualified analytical methods.